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Abstract
Background: To develop a population-based cohort of people with ankylosing spondylitis (AS) in Wales using (1)
secondary care clinical datasets, (2) patient-derived questionnaire data and (3) routinely-collected information in
order to examine disease history and the health economic cost of AS.
Methods: This data model will include and link (1) secondary care clinician datasets (i.e. electronic patient notes
from the rheumatologist) (2) patient completed questionnaires (giving information on disease activity, medication,
function, quality of life, work limitations and health service utilisation) and (3) a broad range of routinely collected
data (including; GP records, in-patient hospital admission data, emergency department data, laboratory/pathology
data and social services databases). The protocol involves the use of a unique and powerful data linkage system
which allows datasets to be interlinked and to complement each other.
Discussion: This cohort can integrate patient supplied, primary and secondary care data into a unified data model.
This can be used to study a range of issues such as; the true economic costs to the health care system and the
patient, factors associated with the development of severe disease, long term adverse events of new and existing
medication and to understand the disease history of this condition. It will benefit patients, clinicians and health
care managers. This study forms a pilot project for the use of routine data/patient data linked cohorts for other
chronic conditions.
Background
Ankylosing Spondylitis (AS) is a chronic inflammatory
arthritis affecting between 1 in 400 and 1 in 270 people
[1,2]. AS is characterised by inflammation of the spine,
resulting in progressive and irreversible fusion of the
spine. Peripheral joints, particularly the hips [3] can also
be involved, often requiring hip replacement surgery. In
a significant number of patients, AS is also associated
with inflammation of other organs such as the heart
[4,5], eyes [6], bowel [7] and skin [8]. In common with
most chronic inflammatory conditions, AS is heteroge-
n e o u s ,h a v i n gav a r i a b l ec o u r s ea n du n p r e d i c t a b l ee p i -
sodes of exacerbation [9].
AS typically strikes people in their late teens or early
adult life and runs for the remainder of the life-course.
It therefore has a significant impact on employment and
function and on the use of health and social care
resources. Over 80% of patients report daily pain, 60%
report daily use of drugs 20 years after diagnosis [10]
and in a Dutch study only 54.2% of the AS cohort were
participating in the labour work force [11].
Our study proposes to collect and link a range of
complementary sets of data; including, robust clinical
data from rheumatologists (diagnosis, MRI/radiograph
images), existing routinely collected datasets such as the
GP records, out-patients clinical data, in-patient activity,
emergency department, laboratory/pathology data and
social services databases and finally data collected
directly from the patients themselves (disease activity,
function, quality of life, work limitations).
Re-use of routine data is problematic and requires
detailed knowledge of the datasets and their idiosyncra-
cies. Information Governance challenges can also be a
problem in such distributed datasets. These problems
have been surmounted by the establishment of the
Health Information Research Unit (HIRU) at the School
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Assembly Government’s commitment to the UK Clinical
Research Collaboration (UKCRC). Its remit is to realise
the potential of electronically held, person-based, routi-
nely collected information to conduct and support
health-related research. HIRU has set up the Secure
Anonymised Information Linkage (SAIL) databank to
bring together, link and anonymise the widest possible
range of person-based data, and has done this using a
split-file approach to anonymisation to overcome issues
of confidentiality and disclosure in health-related data
warehousing [12]. The SAIL databank operates within a
robust series of guidelines in line with the Caldicott
principles and the National Information Governance
Board for Health and Social Care. [13].
The collection and linkage of data proposed here is
unique and not currently feasible elsewhere. Due to the
existing routine data linkages [12] and a new rheumatol-
ogy network incorporating all rheumatologists in Wales,
it is now possible to undertake a national AS cohort
study identifying a well defined and characterised group,
with the intention of expanding this strategy to other
rheumatological conditions in the future.
Methods/Design
Aims
This study aims to develop a cohort of people with AS
using existing data from clinical and routine sources
and data collected from patient completed
questionnaires.
Recruitment and composition of the cohort
All patients living in Wales diagnosed with AS by a
rheumatologist will be included. Examining all GP
records in the Swansea area showed that there are 361
people registered with AS in 2006 out of 239,354 people
registered with a GP. This gives a prevalence of 1.5 per
1000. Extrapolating this figure to the whole of Wales
generates an estimated 4354 people in Wales with a
diagnosis of AS. We plan to write to all patients with
AS attending a rheumatologist in Wales as well as those
registered with participating GPs, to ask for their con-
sent to be included in this cohort. With this combined
approach we anticipate a cohort of 2000 pseudonymised
AS patients or 50% of all available AS patients.
Data sources
The AS cohort will be built on the SAIL data bank [13]
and will use SAIL’s approach to data linkage and anon-
ymity. In this approach, the data provider divides a data
file into two parts; the personal information (name, date
of birth, address, national health number) in the first
part (file 1), and the clinical data in the second (file 2),
with a joining key to link the two parts. The personal
information (file 1) is sent to a third party (Health Solu-
tions Wales) who match the information against a list of
all people registered with the National Health Service in
Wales. In cases where the NHS number is absent, a
mixture of other identifiers is used for probabilistic
matching. This creates a linking number (Anonymised
Linking Field), which is then encrypted to become
ALF_E. The other identifiers are deleted, giving File 3.
File 3 is then sent to HIRU. File 2 is sent directly to
HIRU by the data provider. Files 2 and 3 are then
brought together at the SAIL databank where they are
merged using the joining key, which is then deleted [12].
This growing databank already holds over a billion
anonymised records from 13 databases and these can be
anonymously linked at the individual record level [13].
The SAIL databank has been used in characterising
latent autoimmune diabetes in adults [14], establishing
the hospitalised prevalence of Crohn’s disease and
ulcerative colitis [15], and investigating differences in
blood pressure measurements taken in primary and sec-
ondary care settings [16]. Linkage of routine data to
trial cohorts has been done in relation to identifying
patients for a depression trial [17], to facilitate recruit-
ment for a diabetes trial [18], and to link environmental
information about the domestic circumstances of preg-
nant women with routinely collected child health data
[19].
Thus, the use of this data warehouse in a wide range
of clinical and research settings using combinations of
routinely collected and trial data has been established.
With the triangulation of datasets (comparing the same
data items from different datasets), the validity and relia-
bility of single datasets can be assessed.
Clinical data from Rheumatology centres
All rheumatology centres in Wales are in the process of
adopting the same electronic clinical database system:
Welsh Arthritis and Rheumatology Dataset (WARD).
This is implemented on the CELLMA platform (RioMed
Ltd., Eastleigh, Hampshire, http://www.riomed.com).
WARD will, as a minimum, record all rheumatological
diagnoses, date of diagnoses and medications whenever
the rheumatological teams see a patient, in addition to
providing clinical data support during consultations.
This system can be used to easily identify all patients
with a specific rheumatological diagnosis (such as AS)
across Wales. Historical information about existing
patients will be entered into the WARD system.
In 3 participating centres, a pilot scheme will be car-
ried out to examine the feasibility of using existing
radiographs or MRI reports. The pilot will examine the
numbers of images available and the ease of obtaining
them. If the collection of radiographs and MRIs is feasi-
ble, the radiographs will be scored using both the Stoke
system [20] for lumbar spine and the BASRI system
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and reports will be requested and scored to be included
in the rheumatology clinical dataset and the system will
be rolled this out to the other centres.
Patient self-administered data (PAS cohort)
Many of the validated measures of disease severity in AS
are patient-assessed indices, such as the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) [22] and
the Bath Ankylosing Spondylitis Functional Index
(BASFI) [23].
We have previously demonstrated that these patient
self-administered severity questionnaires for AS can be
delivered over the internet as well as by paper [24] and
have used this system to conduct an internet-delivered
RCT in AS [25]. We have adapted this methodology in
the present study.
As a result of clinical pressures, these measures are cur-
rently not routinely collected by all rheumatologists.
Therefore, all patients coming for an appointment with a
rheumatologist will be asked to complete a paper-based
questionnaire at the visit. As part of the process of consent
to be included in the cohort, patients will be asked to con-
sent to completing a questionnaire every 6 months, either
online if they have internet access, or by post. The con-
tents of the questionnaires are summarised in Table 1.
This data will be fed back into the clinical dataset
(WARD) and will be available to the patients’ rheuma-
tologists to help inform the patients’ ongoing clinical
care. In addition, for those patients not registered with a
rheumatologist in Wales, all consenting patients regis-
tered with the National Ankylosing Spondylitis Society
(NASS) (http://www.nass.co.uk/) and those registered
with participating GPs, will receive postal or internet
versions of the questionnaire.
Questionnaire responses will be linked using the SAIL
process.
A website has been developed to give access to the
questionnaires (http://www.ashealth.co.uk/). It includes
open access sections for news about the cohort project
as well as AS issues in general. There is also a section
giving factsheets about AS, a community page where
members of the AS community can give information
about themselves and a forum where members of the
community can submit posts on any topic.
Within the site, there are pages restricted to people
with AS who are willing to register. The site collects
name and address data as well as the name of the parti-
cipant’s GP. This renders the resulting dataset linkable
via the SAIL mechanism. GPs are written to and asked
to confirm that the patients have AS.
Routine data sources
For the PAS cohort, the data collected on patients with
a diagnosis of AS, as given by the rheumatologist, will
be linked to other routinely collected datasets using the
SAIL system. This linkage will allow us to follow the
patient pathway through the NHS system both retro-
spectively and prospectively. Linkage with GP system
data provides information about patients going back 10
years including; previous diagnosis, presenting symp-
toms, results of laboratory tests and previous medica-
tions. This dataset can be used to follow the patient at
every visit to the GP and therefore record the develop-
ment of associated conditions and co-medication. Link-
age with in-patient data will record all hospital visits,
surgery and treatment. Linkage with the mortality data-
sets will ensure the dataset remains relevant and can
examine survival of included patients. Linkage with A&E
datasets will give informati o no ne m e r g e n c yv i s i t s .T h e
linkage with the GP system can also identify patients
who have a diagnosis of AS but are not currently seen
by a rheumatologist in Wales. Before inclusion into the
cohort, the GPs of these patients will be asked to con-
firm that AS has been diagnosed by a rheumatologist.
This will allow us to gain a full picture of the spectrum
of AS patients, including those living in Wales but see-
ing a specialist elsewhere and those whose AS is not
Table 1 Summary of questionnaires
Questionnaire Time interval Summary
Baseline 0 Co-morbidities, family history, age of diagnosis and first symptoms, BASDAI [22], BASFI [23], QOL [32], visits to
professionals
Not at work 3 months Previous occupation, activity impairment questionnaire
At work 3 months Work limitations questionnaire (WLQ) [38], Work productivity and activity impairment questionnaire (WPAI-SHP)
[39,40]
Follow up 6, 12 months BASDAI [22], BASFI [23], QOL [32], other conditions
AS costs 9 months Visits to professionals, tests done, other conditions, medications, costs of various aspects of treatment and
disability
Exercise and
fatigue
15 month International Physical Activity Questionnaire (IPAQ) [33], BASDAI [22], BASFI [23], Behavioural regulation in exercise
questionnaire (BREQ-2) [34], Pittsburgh Sleep Quality Index [35], Hospital Anxiety and depression Scale [36,37]
Medication 0,3,6,9,12,15
months
Medication
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up. Therefore, the characterisation of AS patients, at all
disease stages can be maximised by the routinely col-
lected data held on them by the NHS and other public
bodies using the existing SAIL databanks.
Ethics
PAS has been granted ethical approval by the London
Research Ethics Committee (08/H0718/64).
Discussion
This cohort takes its participants from GPs (primary
care practitioners) and rheumatologists. The study is
supplemented by patient-supplied information in the
form of a series of questionnaires. Patient consent is
required to include patients in the cohort. In addition,
c o n s e n ti ss o u g h tt ol i n kc o h o r tp a r t i c i p a n t st ot h e
existing databank of routinely collected data currently in
the SAIL system. The ability to link cohort members
anonymously to routinely collected data is one of the
unique features of this cohort. GP data is widely used in
research, and can give a wide range of information
about treatment and associated conditions, but one
must be aware of the various issues of data quality and
completeness concerning primary care records [26].
Other sources of routine data such as in-patient and
out-patient records can also be linked to the cohort and
can help to enhance the data held on each patient.
The cohort will have immediate impact on giving an
objective estimate of the cost of AS at each stage of the
disease which will help inform the use of anti-TNF
agents. This is of immediate importance to many
patients who could benefit from these agents, once
approved by NICE. Patients who potentially meet the
NICE criteria for the anti-TNF agents could be easily
identified as part of this cohort.
The existing routine data from the previous 10 years will
enable retrospective cohort studies to identify early risk
factors (such as early hip involvement [27]) for progression
to severe AS (as defined by the need for surgery or disabil-
ity benefit). These patients could then be selected for
aggressive early treatment with anti-TNF agents.
The cohort can be used to rapidly identify potential
patients for RCTs of anti-TNF agents and other new
drugs. This cohort can be used to screen for specified
inclusion criteria and estimate the numbers eligible for
new trials in the area. This will facilitate recruitment as
the individuals can be identified remotely and invited by
their local rheumatologists or GP to participate in these
studies. The process of screening and recruitment of
participants to trials can then be significantly speeded
up reducing the risk and cost to pharmaceutical compa-
nies, thereby leading to more efficient and cost-effective
trials.
The collection of AS patients can inform the develop-
ment of genetic work in this field and facilitate the
development of potential vaccines and other targeted
therapies as a follow on from this work. Therefore it
will facilitate the UK participation within international
consortiums on genetic research of inflammatory auto-
immune conditions. Once established and phenotyped,
it is intended that this cohort will be used for studies in
conjunction with the rheumatology research networks
established by the Arthritis Research Campaign (ARC).
These future studies include the potential to link the
data from this cohort with biological and genetic sample
banks from consenting patients. There has been a long
history of work looking at the genetics of AS in the UK.
However, there is a bottle-neck in terms of identifying
enough people to conduct repeat validation studies to
confirm the importance of new regions of interest for
susceptibility and severity genes. By far the largest study
in AS genetics to date involved 1000 patients with AS
and 1500 controls [28], while no genome-wide associa-
tion study has yet been done in AS [29]. Historically,
these studies have not tended to use patients from
Wales for logistical reasons as it has previously been dif-
ficult to identify these patients. Therefore this well char-
acterised cohort, together with the collection of newly
diagnosed AS patients, would enhance the ability of
researchers in the UK to conduct these validation stu-
dies. Linking genetic and biological samples with the
routinely collected clinical data would also allow the
investigation and identification of associations not possi-
ble by other means.
Phenotyping patients would include collecting mea-
sures that reflect the expression of the disease without
describing the actual genetic make-up of the patient. In
the case of AS, this would include; medically held data
such as first symptoms, disease history and develop-
ment, areas affected, co-disorders, severity, family
history, age at onset, environmental data such as socio-
economic status, physical activity levels, medications,
inherent modifiers such as sex, ethnicity and finally bio-
chemical/immunological measures from the laboratory
such as markers for inflammation. Much of this data
can be obtained from existing routine data and from the
patient.
The cohort can be used to work with family members
of AS patients in order to identify individuals at high
risk of developing AS (such as the children of AS-
affected women with a young age at onset [30]) to
examine the early disease history of AS pre-diagnosis
(using MRI scans) in order to examine interventions
which may switch off or prevent AS.
This study therefore builds on and enhances existing
UK resources and infrastructure. The methods used in
this study are also relevant to other chronic conditions,
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phenotyping cohorts using the linkage of routine, clini-
cal and patient-entered data.
This cohort will also allow easy collection of post-RCT
and post-marketing surveillance data, which is crucial
for new biologic agents whose long-term effects are
unknown. The British Society for Rheumatology (BSR)
is currently piloting measures and data collection for
the development of a Disease Management Register for
AS, including a biologics register [31] The PAS cohort
could be used to directly contribute to and enhance this
national register.
Thus, in conclusion the cohort can be used for a wide
variety of research studies (burden/cost of disease, dis-
ease history, trial recruitment, genetic research, basic
research of biological markers, and post trial surveil-
lance). This is a pilot for undertaking the same method
of cohort development in other chronic conditions.
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